Red blood cell transfusion in sickle cell patients

Detalhes bibliográficos
Autor(a) principal: Barros, Rawanderson Ferreira Lima
Data de Publicação: 2019
Outros Autores: Silva, Roniel Resplandes da, Mota, Mara Soares de Almeida, Andrade, Simone Pôssas
Tipo de documento: Artigo
Idioma: por
Título da fonte: Scire Salutis
Texto Completo: https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007
Resumo: Sickle cell anemia is a prevalent disease in Brazil, and is characterized by a genetic mutation that causes deformity in the red blood cells of the carrier, causing several problems. A good part of these patients need frequent transfusions to treat complications of the disease, but over time there may be complications resulting from these transfusions, which makes the use of this therapy very careful. But why can sickle cell patients have problems with transfusion therapy? Due to the frequency of transfusions, the sickle cell patient may be alloimmunized against antigens from various blood group systems. The best way to prevent this type of reaction is to perform red cell phenotyping for compatibility testing. The present study aimed to address the red blood cell transfusion in sickle cell patients, also listing the reactions that may occur due to this therapy and the procedures that should be taken to avoid such reactions, also addressing the role of the biomedical in this process. It is a literary research conducted based on national and international scientific articles, monographs, laws and books that were selected using as a criterion the approach of the chosen theme. We used as research sources the sites SCIELO (Scientific Electronic Library Online), Pubmed, Virtual Library of the Ministry of Health and books present in the physical and virtual library of the Educational Institute Santa Catarina (IESC). Transfusion therapy is a great option to treat the complications of sickle cell anemia, but measures should be used to prevent post-transfusion problems.
id ESS-1_30806ee44e3d7ba46a9a26c5deeb3fde
oai_identifier_str oai:ojs.pkp.sfu.ca:article/2663
network_acronym_str ESS-1
network_name_str Scire Salutis
repository_id_str
spelling Red blood cell transfusion in sickle cell patientsTransfusão de hemácias em pacientes falcêmicosAnemia FalciformeAloimunizaçãoTransfusãoSickle cell anemiaAlloimmunizationTransfusionSickle cell anemia is a prevalent disease in Brazil, and is characterized by a genetic mutation that causes deformity in the red blood cells of the carrier, causing several problems. A good part of these patients need frequent transfusions to treat complications of the disease, but over time there may be complications resulting from these transfusions, which makes the use of this therapy very careful. But why can sickle cell patients have problems with transfusion therapy? Due to the frequency of transfusions, the sickle cell patient may be alloimmunized against antigens from various blood group systems. The best way to prevent this type of reaction is to perform red cell phenotyping for compatibility testing. The present study aimed to address the red blood cell transfusion in sickle cell patients, also listing the reactions that may occur due to this therapy and the procedures that should be taken to avoid such reactions, also addressing the role of the biomedical in this process. It is a literary research conducted based on national and international scientific articles, monographs, laws and books that were selected using as a criterion the approach of the chosen theme. We used as research sources the sites SCIELO (Scientific Electronic Library Online), Pubmed, Virtual Library of the Ministry of Health and books present in the physical and virtual library of the Educational Institute Santa Catarina (IESC). Transfusion therapy is a great option to treat the complications of sickle cell anemia, but measures should be used to prevent post-transfusion problems.A anemia falciforme é uma doença prevalente no Brasil, e é caracterizada por uma mutação genética que provoca uma deformidade nas hemácias do portador, causando diversos problemas. Uma boa parte desses pacientes necessitam de transfusões frequentes para tratamento de complicações da doença, porém, ao longo do tempo podem surgir complicações resultantes dessas transfusões, o que torna o uso dessa terapia bastante criteriosa. Mas por que o paciente falciforme pode apresentar problemas com a terapia transfusional? Devido a frequência de transfusões, o paciente falcêmico pode sofrer uma aloimunização contra antígenos de vários sistemas de grupos sanguíneos. A melhor forma de prevenir esse tipo de reação é realizando a fenotipagem das hemácias para teste de compatibilidade. O presente estudo teve como objetivo abordar sobre a transfusão de hemácias em pacientes falcêmicos, elencando também as reações que podem ocorrer em função dessa terapia e os procedimentos que devem ser tomados para evitar tais reações, abordando também o papel do biomédico nesse processo. Trata-se de uma pesquisa literária realizada com base em artigos científicos nacionais e internacionais, monografias, leis e livros que foram selecionados utilizando como critério a abordagem do tema escolhido. Foram utilizados como fontes de pesquisa os sites SCIELO (Scientific Electronic Library Online), Pubmed, Biblioteca Virtual do Ministério da Saúde e livros presentes na biblioteca física e virtual do Instituto Educacional Santa Catarina (IESC). A terapia transfusional é uma ótima opção de tratamento das complicações da anemia falciforme, porém devem ser utilizadas medidas para prevenir os problemas pós-transfusionais.Sustenere Publishing2019-06-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.000710.6008/CBPC2236-9600.2019.001.0007Scire Salutis; Vol. 9 No. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61Scire Salutis; Vol. 9 Núm. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61Scire Salutis; v. 9 n. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-612236-9600reponame:Scire Salutisinstname:Companhia Brasileira de Produção Científica (CBPC)instacron:ESSporhttps://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007/1499Copyright (c) 2019 Scire Salutisinfo:eu-repo/semantics/openAccessBarros, Rawanderson Ferreira LimaSilva, Roniel Resplandes daMota, Mara Soares de AlmeidaAndrade, Simone Pôssas2020-01-08T10:56:39Zoai:ojs.pkp.sfu.ca:article/2663Revistahttps://sustenere.co/index.php/sciresalutisONGhttps://sustenere.co/index.php/sciresalutis/oai||carlos@arvore.org.br2236-96002236-9600opendoar:2020-01-08T10:56:39Scire Salutis - Companhia Brasileira de Produção Científica (CBPC)false
dc.title.none.fl_str_mv Red blood cell transfusion in sickle cell patients
Transfusão de hemácias em pacientes falcêmicos
title Red blood cell transfusion in sickle cell patients
spellingShingle Red blood cell transfusion in sickle cell patients
Barros, Rawanderson Ferreira Lima
Anemia Falciforme
Aloimunização
Transfusão
Sickle cell anemia
Alloimmunization
Transfusion
title_short Red blood cell transfusion in sickle cell patients
title_full Red blood cell transfusion in sickle cell patients
title_fullStr Red blood cell transfusion in sickle cell patients
title_full_unstemmed Red blood cell transfusion in sickle cell patients
title_sort Red blood cell transfusion in sickle cell patients
author Barros, Rawanderson Ferreira Lima
author_facet Barros, Rawanderson Ferreira Lima
Silva, Roniel Resplandes da
Mota, Mara Soares de Almeida
Andrade, Simone Pôssas
author_role author
author2 Silva, Roniel Resplandes da
Mota, Mara Soares de Almeida
Andrade, Simone Pôssas
author2_role author
author
author
dc.contributor.author.fl_str_mv Barros, Rawanderson Ferreira Lima
Silva, Roniel Resplandes da
Mota, Mara Soares de Almeida
Andrade, Simone Pôssas
dc.subject.por.fl_str_mv Anemia Falciforme
Aloimunização
Transfusão
Sickle cell anemia
Alloimmunization
Transfusion
topic Anemia Falciforme
Aloimunização
Transfusão
Sickle cell anemia
Alloimmunization
Transfusion
description Sickle cell anemia is a prevalent disease in Brazil, and is characterized by a genetic mutation that causes deformity in the red blood cells of the carrier, causing several problems. A good part of these patients need frequent transfusions to treat complications of the disease, but over time there may be complications resulting from these transfusions, which makes the use of this therapy very careful. But why can sickle cell patients have problems with transfusion therapy? Due to the frequency of transfusions, the sickle cell patient may be alloimmunized against antigens from various blood group systems. The best way to prevent this type of reaction is to perform red cell phenotyping for compatibility testing. The present study aimed to address the red blood cell transfusion in sickle cell patients, also listing the reactions that may occur due to this therapy and the procedures that should be taken to avoid such reactions, also addressing the role of the biomedical in this process. It is a literary research conducted based on national and international scientific articles, monographs, laws and books that were selected using as a criterion the approach of the chosen theme. We used as research sources the sites SCIELO (Scientific Electronic Library Online), Pubmed, Virtual Library of the Ministry of Health and books present in the physical and virtual library of the Educational Institute Santa Catarina (IESC). Transfusion therapy is a great option to treat the complications of sickle cell anemia, but measures should be used to prevent post-transfusion problems.
publishDate 2019
dc.date.none.fl_str_mv 2019-06-20
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007
10.6008/CBPC2236-9600.2019.001.0007
url https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007
identifier_str_mv 10.6008/CBPC2236-9600.2019.001.0007
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://sustenere.inf.br/index.php/sciresalutis/article/view/CBPC2236-9600.2019.001.0007/1499
dc.rights.driver.fl_str_mv Copyright (c) 2019 Scire Salutis
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Scire Salutis
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sustenere Publishing
publisher.none.fl_str_mv Sustenere Publishing
dc.source.none.fl_str_mv Scire Salutis; Vol. 9 No. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61
Scire Salutis; Vol. 9 Núm. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61
Scire Salutis; v. 9 n. 1 (2019): Scire Salutis - Out, Nov, Dez 2018, Jan 2019; 50-61
2236-9600
reponame:Scire Salutis
instname:Companhia Brasileira de Produção Científica (CBPC)
instacron:ESS
instname_str Companhia Brasileira de Produção Científica (CBPC)
instacron_str ESS
institution ESS
reponame_str Scire Salutis
collection Scire Salutis
repository.name.fl_str_mv Scire Salutis - Companhia Brasileira de Produção Científica (CBPC)
repository.mail.fl_str_mv ||carlos@arvore.org.br
_version_ 1793890277762531328